21-02-2005: Biotest AG and Lonza have concluded a manufacturing agreement in January 2005 for further production of GMP grade consistency batches of Biotest´s monoclonal antibody BT-061. The production, which has already commenced this week supplies Biotest with material for further clinical studies. In addition, this agreement opens up the option on future large scale production with the technological leader Lonza.
BT-061 is directed against a novel target on T-cells mediating a unique, immunoregulatory mechanism of action. The candidate is Biotest´s most advanced monoclonal antibody and has shown tolerability and efficacy in early clinical trials in patients with rheumatoid arthritis. With the clinical material produced by Lonza Biologics, Slough, UK, development will continue in rheumatoid arthritis and psoriasis.